Full-Service, Scalable Solution Designed to
Help Health Systems Establish and Continuously Optimize Centralized
Medication Management Operations
Omnicell, Inc. (Nasdaq:OMCL), a leader in transforming the
pharmacy care delivery model, today announced Central Med
Automation Service, a subscription-based solution designed to help
health systems establish and continuously optimize centralized
medication management for Consolidated Pharmacy Services Centers
(CPSCs) and similar operations. Central Med Automation Service is
intended to streamline medication dispensing from a central
fulfillment area throughout the entire health system enterprise,
which is expected to enhance inventory visibility, scalability, and
patient safety.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240820888541/en/
Introducing Omnicell Central Med
Automation Service, a full-service, scalable solution designed to
help health systems establish and continuously optimize centralized
medication management operations (Graphic: Business Wire)
“As the health system enterprise grows, we find that traditional
methods of medication management can lead to multi-vendor
environments that may complicate workflows, often creating
unnecessary redundancy and increasing chances for error,” said
Randall Lipps, chairman, president, chief executive officer, and
founder of Omnicell. “Pharmacy leaders recognize the potential
value of centralizing pharmacy services, but often lack the capital
budgets, resources, and expertise necessary to transform their
infrastructure and scale it over time. Omnicell’s Central Med
Automation Service is designed to help health systems develop and
execute a central fill strategy while providing the expert support
necessary to help ensure this environment meets current and future
medication management needs.”
Central Med Automation Service is intended to seamlessly
integrate enterprise-wide robotics, smart devices, and intelligent
software with expert services in an effort to help health systems
establish and continuously optimize their centralized pharmacy
operations to support medication management at acute care, remote
clinics, and community sites. Central Med Automation Service
includes:
Robotics & Smart
Devices
XR2 Automated Central Pharmacy System:
Advanced medication storage and dispensing robotics are designed to
automate critical fulfillment workflows, decrease human error, and
maximize inventory control. With 100% barcode scanning and
soonest-to-expire dispense capability, these robotics aim to
improve inventory visibility, enhance efficiency, and increase
patient safety – which should free pharmacy staff to focus on
clinical initiatives rather than manual tasks.
Software
Central Pharmacy Manager for Central Med
Automation Service: This intelligent software is specifically
designed to support centralized medication management workflows
within a CPSC, including medication ordering, receiving, picking,
verifying, and restocking. The Central Pharmacy Manager for Central
Med Automation Service features enhanced processing power that is
meant to handle high medication transaction volumes while
streamlining distribution workflows within the central fulfillment
environment.
Inventory Optimization Service: A
combination of software and expert services, this solution is
intended to provide enterprise-wide inventory visibility and
management of medication par levels, expiration dates, and usage
patterns delivered through data-rich dashboards.
Expert
Services
Upfront and Ongoing Guidance: Omnicell
experts work with each customer to tailor Central Med Automation
Service to a customer’s specific needs, including initial
medication storage, distribution, and personnel workflows. Ongoing,
data-informed monitoring and updates are intended to ensure
continuous operational optimization, efficiency, and patient safety
for health system enterprises.
Continuous On-site Support: Dedicated
on-site assistance to operate robotics and smart devices is
designed to support round-the-clock operational efficiency and
productivity.
KPI Performance Tracking: Omnicell
expert services utilize data analytics to deliver operational
performance metrics, helping to enable informed decision-making and
continuous improvement in efficiency.
Several complementary robotics, smart devices, and software
tools can be added to extend the capabilities and potential value
of Central Med Automation Service. These include Omnicell’s suite
of pharmacy carousels and packagers, 340B program management
software, and Central Pharmacy Manager Mobile Workstation, a new
offering that is designed to untether pharmacy personnel from fixed
terminals to accelerate order fulfillment.
“Medications are complex and managing them is even more complex,
particularly at a time when we’re challenged with growing drug and
pharmacy technician shortages,” said Nilesh Desai, RPh, CPPS, chief
pharmacy officer at Baptist Health. “Centralizing pharmacy services
helps us address these challenges in an effort to provide better
and safer care to our patients and communities. Achieving this
vision would not have been possible without business partners like
Omnicell who, through Central Med Automation Service, have a stake
in the game to make us successful.”
Central Med Automation Service provides the flexibility to
support hub and spoke, warehouse, and hybrid approaches to
centralizing pharmacy operations, which is intended to help health
systems move closer to the industry vision of the Autonomous
Pharmacy that seeks to replace manual, error-prone activities with
automated processes that are safer and more efficient.
Learn more at omnicell.com/CentralMedAutomationService.
About Omnicell
Since 1992, Omnicell has been committed to transforming pharmacy
care through outcomes-centric innovation designed to optimize
clinical and business outcomes across all settings of care. Through
a comprehensive portfolio of robotics, smart devices, intelligent
software, and expert services, Omnicell solutions are helping
healthcare facilities worldwide to reduce costs, improve labor
efficiency, establish new revenue streams, enhance supply chain
control, support compliance, and move closer to the industry vision
of the Autonomous Pharmacy. To learn more, visit omnicell.com.
From time to time, Omnicell may use the Company’s investor
relations website and other online social media channels, including
its Twitter handle www.twitter.com/omnicell, LinkedIn page
www.linkedin.com/company/omnicell, and Facebook page
www.facebook.com/omnicellinc, to disclose material non-public
information and comply with its disclosure obligations under
Regulation Fair Disclosure (“Reg FD”).
OMNICELL and the Omnicell logo are registered trademarks of
Omnicell, Inc. or one of its subsidiaries.
Forward-Looking Statements
To the extent any statements contained in this press release
deal with information that is not historical, these statements are
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. Without limiting the
foregoing, statements including the words “expect,” “intend,”
“may,” “will,” “should,” “would,” “could,” “plan,” “potential,”
“anticipate,” “believe,” “forecast,” “guidance,” “outlook,”
“goals,” “target,” “estimate,” “seek,” “predict,” “project,” and
similar expressions are intended to identify forward-looking
statements. Forward-looking statements are subject to the
occurrence of many events outside Omnicell’s control. Such
statements include, but are not limited to, Omnicell’s planned new
products and services or developing enhancements to existing
products and services, including Central Med Automation Service and
the related objectives and expected benefits (and any implied
financial impact), and statements about Omnicell’s strategy, plans,
objectives, promise and purpose, goals, opportunities, and market
or Company outlook. Actual results and other events may differ
significantly from those contemplated by forward-looking statements
due to numerous factors that involve substantial known and unknown
risks and uncertainties. These risks and uncertainties include,
among other things, (i) unfavorable general economic and market
conditions, including the impact and duration of inflationary
pressures, (ii) Omnicell’s ability to take advantage of growth
opportunities and develop and commercialize new solutions and
enhance existing solutions, (iii) reduction in demand in the
capital equipment market or reduction in the demand for or adoption
of our solutions, systems, or services, (iv) delays in
installations of our medication management solutions or our more
complex medication packaging systems, (v) risks related to
Omnicell’s investments in new business strategies or initiatives,
including its transition to selling more products and services on a
subscription basis (vi) risks related to failing to maintain
expected service levels when providing our Advanced Services or
retaining our Advanced Services customers, (vii) Omnicell’s ability
to meet the demands of, or maintain relationships with, its
institutional, retail, and specialty pharmacy customers, (viii)
continued and increased competition from current and future
competitors in the medication management automation solutions
market and the medication adherence solutions market, (ix) risks
presented by government regulations, legislative changes, fraud and
anti-kickback statues, products liability claims, the outcome of
legal proceedings, and other legal obligations related to
healthcare, privacy, data protection, and information security,
including any potential governmental investigations and enforcement
actions, litigation, fines and penalties, exposure to
indemnification obligations or other liabilities, and adverse
publicity as a result of the previously disclosed ransomware
incident, (x) any disruption in Omnicell’s information technology
systems and breaches of data security or cyber-attacks on its
systems or solutions, including the previously disclosed ransomware
incident and any potential adverse legal, reputational, and
financial effects that may result from it and/or additional
cybersecurity incidents, as well as the effectiveness of business
continuity plans during any future cybersecurity incidents,
countries, (xi) Omnicell’s ability to recruit and retain skilled
and motivated personnel, (xii) Omnicell’s ability to protect its
intellectual property, (xiii) risks related to the availability and
sources of raw materials and components or price fluctuations,
shortages, or interruptions of supply, (xiv) Omnicell’s dependence
on a limited number of suppliers for certain components, equipment,
and raw materials, as well as technologies provided by third-party
vendors, and (xv) other risks and uncertainties further described
in the “Risk Factors” section of Omnicell’s most recent Annual
Report on Form 10-K, as well as in Omnicell’s other reports filed
with or furnished to the United States Securities and Exchange
Commission (“SEC”), available at www.sec.gov. Forward-looking
statements should be considered in light of these risks and
uncertainties. Investors and others are cautioned not to place
undue reliance on forward-looking statements. All forward-looking
statements contained in this press release speak only as of the
date of this press release. Omnicell assumes no obligation to
update any such statements publicly, or to update the reasons
actual results could differ materially from those expressed or
implied in any forward-looking statements, whether as a result of
changed circumstances, new information, future events, or
otherwise, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240820888541/en/
Betsy Martinelli Director, Corporate Marketing
betsy.martinelli@omnicell.com
Omnicell (NASDAQ:OMCL)
Gráfico Histórico do Ativo
De Fev 2025 até Mar 2025
Omnicell (NASDAQ:OMCL)
Gráfico Histórico do Ativo
De Mar 2024 até Mar 2025
